Phase 2 trial

Dianthus Therapeutics (DNTH) will report topline results from its Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) on September 8, 2025, at 8:00 a.m. EDT. The clinical-stage biotech company, focused on antibody complement therapeutics for autoimmune diseases, will host a conference call and webcast with a Q&A session. Investors can access the webcast via the company’s investor relations website, with a replay available afterward. Claseprubart targets the classical complement pathway, potentially offering a targeted gMG treatment.

Actuate Therapeutics announced positive Phase 2 results for elraglusib in previously untreated metastatic pancreatic cancer. The combination with gemcitabine/nab-paclitaxel significantly improved overall survival to 10.1 months, compared to 7.2 months for the control, with a 37% reduction in death risk. The 12-month survival rate also doubled. Actuate plans to discuss product registration with the FDA.